Synonyms containing ampliphi biosciences
We've found 86 synonyms:
AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.
Pacific Biosciences is a biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. They describe their platform as single molecule real time sequencing, based on the properties of zero-mode waveguides. Their first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011. A new version of the sequencer called the PacBio RS II was released in April 2013. On 25 September 2013 a partnership between Pacific Biosciences and Roche Diagnostics was announced for the development of in vitro diagnostic products using the technology, with Roche providing $75 million dollars in the deal.
|California Institute for Quantitative Biosciences (QB3)|
California Institute for Quantitative Biosciences (QB3)
The California Institute for Quantitative Biosciences (QB3) is a nonprofit research and technology commercialization institute spanning three University of California campuses in the San Francisco Bay Area: UC Berkeley, UCSF, and UC Santa Cruz. QB3's domain is the quantitative biosciences: areas of biology in which advances are chiefly made by scientists applying techniques from physics, chemistry, engineering, and computer science.
Kosan Biosciences, Inc., is a pharmaceutical company which deals with cancer therapeutics medications. The company is currently working on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 inhibitors and epothilones. Their technology platform is based on manipulation of the genetic instructions of microbes for making natural product polyketides. Rearranging the modular units in natural polyketide synthases, combining modules from different enzymes, and incorporating novel synthetic chemical starter units enables them to produce a wide variety of novel polyketides that would be difficult to obtain via organic synthesis alone. Founded in 1995, Kosan is headquartered in Hayward, California and currently has approximately 90 employees. Kosan was funded in part as a venture capital start-up with funds from Sofinnova Ventures of California. On June 26, 2008, Kosan Biosciences was acquired by Bristol-Myers Squibb.
Botucatu is a city in the southeastern region of Brazil and is located 224.8 km from São Paulo,the Capital of the State of São Paulo. The population is 139,483 (2015 est.) in an area of 1,482.64 km2 (572 sq mi). It lies on top of a plateau (804 meters high). Botucatu became a municipality in 1855, and a city in 1876.The region has humid-subtropical weather, with dry cold winters and hot wet summers. During winter the temperature rarely falls below 2 °C (36 °F). During most of the year, mainly at night, a breeze blowing over São Paulo plateau, from which Botucatu elevates about 200 m, cools the city and surroundings, this cold everyday wind from the high plateaus is where the city got its name from. Botucatu's biggest employer is UNESP, one of the three São Paulo state universities, one of the top universities in all of Latin America and part of several World Top Universities list, making the city an important center for medical research and education. In particular, the city has two campuses, one centered on biomedical sciences, including a school of medicine, an Institute of Biosciences and school of veterinarian sciences, and the other centered on agricultural sciences. The leading industrial company is Embraer through a subsidiary Neiva, that has a multipurpose plant there but primarily the manufacture of EMB 201 "Ipanemao" crop spraying aircraft. Along with Rondonópolis and Ribeiro Preto it is one of the centers of the large Brazilian airborne spraying industry. The city has also two bus bodyworks builders, the Brazilian Induscar and the Basque Irizar. Besides UNESP, there are other private colleges. The city boasts a higher than usual elementary and mid-level educational network, including public and private institutions. It is also an important center for "organic" agriculture being the site of a recognized certification body.
Amit Nilkanth Patel MD, BS, MS is an American-born-Indian cardiac surgeon and was director of clinical regenerative medicine and tissue engineering at the University of Utah in Salt Lake City. He was a tenured professor of surgery - cardiothoracic at the University of Utah until he left for the University of Miami. Patel studied medicine at the Case Western Reserve University. In 2002, he led a "breakthrough" study demonstrating that stem cell transplantation could treat congestive heart failure. He is currently the national lead investigator for Aastrom Biosciences now Vericel Corp to treat cardiomyopathy both ischemic and non-ischemic using adult stem cells in the U.S. He just completed and published the largest heart failure trial for cell therapy in patients with ischemic heart failure. The trial was published in the journal Lancet and demonstrated a 37% reduction in death and hospitalizations for patients with severe heart failure. He is also lead investigator for a number of trials to use adult stem cells to treat limb ischemia (inadequate blood flow to the leg). He has taught many surgeons around the world in countries such as Thailand and India.
|Open Journals Nigeria|
Open Journals Nigeria
Open Journals Nigeria is an "Open Access" academic journal publisher, providing peer-reviewed scholarly journals that facilitate an effective access to high "quality and original" research findings within the domains of Natural and Applied Sciences, Engineering and Technology, Social Science and Humanities and, Medical and Biosciences including broad interest titles and scope. All original research articles published by Open Journals Nigeria are made freely and permanently accessible online immediately upon publication. Open Journals Nigeria (OJN) is sustained by supporting authors' contribution, volunteer services and donations. OJN relies heavily on the academic and research experience of senior Nigerian academics (together with foreign faculty members) who man the editorial boards of its various journals to ensure 100% quality and plagiarism-proof publication.
— Editors Contribution
EraGen Biosciences, Inc., a biotechnology company, develops, manufactures, and markets molecular reagent products and software for research and clinical testing markets. The company offers molecular diagnostic assays for the early detection and monitoring of cancer, genetic, and infectious diseases, as well as for genetic-based conditions. Its products include molecular diagnostic tests, analyte specific reagents, in vitro diagnostic reagents, and research use only reagents; MultiCode-PLx Analysis Software that allows users to create customized templates for plate and assay layouts; and MultiCode-RTx Analysis Software, which enables users to create templates for quantitative and qualitative analyses. The company serves clinical laboratories and medical researchers. It sells its products through distributors in the United States and Canada. The company was founded as Sulfonics, Inc. in 1994 and changed its name to EraGen Biosciences, Inc. in 1999. EraGen Biosciences, Inc. is based in Madison, Wisconsin.
Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company™s product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.
Pressure BioSciences, Inc. (PBI), a life sciences company, engages in the research, development, and commercialization of sample preparation system. It focuses on the development of a platform technology, called pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The company offers Barocycler instrument and an internally developed disposable PULSE (Pressure Used to Lyse Samples for Extraction) Tubes, which together make up the PCT sample preparation system. It holds 13 U.S. and 5 foreign patents covering multiple applications of PCT in the life sciences field. PCT has applications in a various life sciences areas, including sample preparation for genomic, proteomic, and small molecule studies; control of chemical (enzymatic) reactions; protein purification; pathogen inactivation; immunodiagnostics; DNA sequencing; and food safety. PBI™s customers include academic laboratories, government agencies, and biotechnology companies. The company was founded in 1978. It was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in 2004. Pressure BioSciences is based in South Easton, Massachusetts.
Regado Biosciences, Inc., a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. Regado Biosciences, Inc. was formerly known as Quartet Biosciences, Inc. The company was incorporated in 2001 and is based in Durham, North Carolina.
Filgrastim is a granulocyte colony-stimulating factor analog used to stimulate the proliferation and differentiation of granulocytes. It is produced by recombinant DNA technology. The gene for human granulocyte colony-stimulating factor is inserted into the genetic material of Escherichia coli. The G-CSF then produced by E. coli is different from G-CSF naturally made in humans. It is marketed by Amgen under the brand name Neupogen, in India it is also marketed by Abbott Healthcare under the brand name Imumax, Dr. Reddy's Laboratories under the brand name Grafeel, Zenotech Laboratories Limited under the brand name Nugraf, Raichem lifesciences under the brand name Shilgrast, Intas Biopharmaceuticals under the brand name Neukine, Emcure biopharmaceuticals under the brand name Emgrast, Reliance Life Sciences under the brand name Religrast and Sandoz under the name Zarzio. Apricus Biosciences is currently developing and testing a product which can deliver filgrastim through the skin to improve post-chemotherapy recovery of neutrophil counts.
Matrigel is the trade name for a gelatinous protein mixture secreted by Engelbreth-Holm-Swarm mouse sarcoma cells and marketed by BD Biosciences and by Trevigen Inc under the name Cultrex BME. This mixture resembles the complex extracellular environment found in many tissues and is used by cell biologists as a substrate for cell culture. A common laboratory procedure is to dispense small volumes of chilled Matrigel onto plastic tissue culture labware. When incubated at 37 °C the Matrigel proteins self-assemble producing a thin film that covers the surface of the labware. Cells cultured on Matrigel demonstrate complex cellular behavior that is otherwise difficult to observe under laboratory conditions. For example, endothelial cells create intricate spiderweb-like networks on Matrigel coated surfaces but not on plastic surfaces. Such networks are highly suggestive of the microvascular capillary systems that suffuse living tissues with blood. Hence, the process by which endothelial cells construct such networks is of great interest to biological researchers and Matrigel allows them to observe this. In some instances researchers may prefer to use greater volumes of Matrigel to produce thick three-dimensional gels. The utility of thick gels is that they induce cells to migrate from the surface to the interior of the gel. This migratory behavior is studied by researchers as a model of tumor cell metastasis.
Systems biology is an emerging approach applied to biomedical and biological scientific research. Systems biology is a biology-based inter-disciplinary field of study that focuses on complex interactions within biological systems, using a more holistic perspective approach to biological and biomedical research. Particularly from year 2000 onwards, the concept has been used widely in the biosciences in a variety of contexts. One of the outreaching aims of systems biology is to model and discover emergent properties, properties of cells, tissues and organisms functioning as a system whose theoretical description is only possible using techniques which fall under the remit of systems biology. These typically involve metabolic networks or cell signaling networks.
Robert Charles Gallo is an American biomedical researcher. He is best known for his role in the discovery of the human immunodeficiency virus, the infectious agent responsible for acquired immune deficiency syndrome, and he has been a major contributor to subsequent HIV research. Gallo is the director of the Institute of Human Virology at the University of Maryland School of Medicine in Baltimore, Maryland. He and two longtime scientific collaborators, Robert R. Redfield and William A. Blattner, co-founded the institute in 1996 in a partnership including the State of Maryland and the City of Baltimore. In 2005, Gallo co-founded Profectus BioSciences, Inc., which develops and commercializes technologies to reduce the morbidity and mortality caused by human viral diseases, including HIV. Gallo was born in Waterbury, Connecticut to a working-class family of Italian immigrants. He earned a BS degree in Biology in 1959 from Providence College and received an MD from Jefferson Medical College in Philadelphia, Pennsylvania in 1963. After completing his medical residency at the University of Chicago, he became a researcher at the National Cancer Institute. Gallo states that his choice of profession was influenced by the early death of his sister from leukemia, a disease to which he initially dedicated much of his research.